Quest for the right Drug

|
עמוד הבית / איומרון 350 / מידע מעלון לרופא

איומרון 350 IOMERON 350 (IOMEPROL)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

תוך-ורידי, תוך-עורקי : I.V, INTRA-ARTERIAL

צורת מינון:

תמיסה להזרקה : SOLUTION FOR INJECTION

Special Warning : אזהרת שימוש

4.4 Special warnings and precautions for use
In consideration of possible complications, the patient should be kept under observation for at least 30 minutes after the examination.
Extreme caution during injection of contrast media is necessary to avoid extravasation.

Hydration
Patients must be well hydrated, and any relevant abnormalities of fluid or electrolyte balance should be corrected prior to and following contrast media injection. Especially patients with diabetes mellitus, polyuria, oligouria, hyperuricaemia, infants, small children and elderly patients, should not be exposed to dehydration.
Also patients with severely compromised hepatic and renal impairment are more at risk. Caution should be exercised in hydrating patients with underlying conditions that may be worsened by fluid overload, including congestive heart failure.

Rehydration prior to use of iomeprol is recommended in patients with sickle cell disease.

Special population
Hypersensitivity to iodinated contrast media, allergic predisposition A positive history of allergy, asthma or untoward reaction during previous similar investigations indicates a need for extra caution since, as with other contrast media, this product may provoke anaphylaxis or other manifestations of allergy with nausea, vomiting, dyspnoea, erythema, urticaria and hypotension. The benefits should clearly outweigh the risks in such patients and appropriate resuscitative measures should be immediately available. The primary treatments are as follows:

Effect                         Major Symptoms           Primary Treatment 

Vasomotor effect               warmth                   reassurance nausea/vomiting
Cutaneous                      scattered hives  H1 -antihistamines severe urticaria H2 -antihistamines
Bronchospastic                 wheezing         oxygen
Beta-2-agonist inhalers
Anaphylactoid reaction     angioedema           oxygen urticaria            IV fluids bronchospasm         adrenergics (iv epinephrine) hypotension          Inhaled beta-2-adrenergics antihistamines (H1-and H2- blockers) corticosteroids
Hypotensive                hypotension          iv fluids
Vagal reaction             hypotension          iv fluids bradycardia          iv atropine
From: Bush WH; The Contrast Media Manual; Katzburg RW Ed.; Williams and Wilkins; Baltimore 1992; Chapter 2 p 23

The risk of bronchospasm-inducing reactions in asthmatic patients is higher after contrast media administration, especially in patients taking beta-blockers.

Hypersensitivity testing
In patients with suspected or known hypersensitivity to contrast media, sensitivity test doses are not recommended, as severe or fatal reactions to contrast media are not predictable from sensitivity test.
Myelomatosis or paraproteinaemias are conditions predisposing to renal impairment following CM administration. The benefits of the use of a contrast-enhanced procedure should be carefully weighted against the possible risk. Adequate hydration and monitoring of renal function are recommended after CM administration.

Cardiovascular diseases
Care should be taken in severe cardiac disease particularly heart failure and coronary artery disease. Reactions may include pulmonary oedema, haemodynamic changes, ischaemic ECG changes and arrhythmias. In severe, chronic hypertension the risk of renal damage following administration of a contrast medium is increased. In these cases the risks associated with the catheterization procedure are increased.

Thyroid function and thyroid function tests
The small amount of free inorganic iodide that may be present in contrast media might have some effects on thyroid function. These effects appear more evident in patients with latent or overt hyperthyroidism or goitre.
Hyperthyroidism or even thyroid storms have been reported following administration of iodinated contrast media.
Thyroid function tests indicative of hypothyroidism or transient thyroid suppression have been reported following iodinated contrast media administration to adult and paediatric patients, including infants. Some patients were treated for hypothyroidism. See also section on Paediatric population.

The administration of iodinated contrast media may aggravate myasthenia signs and symptoms.
CNS Disorders
Particular care is needed in patients with acute cerebral infarction, acute intracranial haemorrhage and any conditions involving damage to the blood brain barrier, brain oedema or acute demyelination. Convulsive seizures are more likely in patients with intracranial tumours or metastases or with a history of epilepsy.
Neurological symptoms related to cerebrovascular diseases, intracranial tumours/metastases or degenerative or inflammatory pathologies may be exacerbated.
There is an increased risk of transient neurological complications in patients with symptomatic cerebrovascular disease e.g. stroke, transient ischaemic attacks. Cerebral ischaemic phenomena may be caused by intravascular injection.
Anticonvulsant therapy should not be discontinued.
Contrast induced encephalopathy
Encephalopathy has been reported with the use of iomeprol (see section 4.8).
Contrast encephalopathy may manifest with symptoms and signs of neurological dysfunction such as headache, visual disturbance, cortical blindness, confusion, seizures, loss of coordination, hemiparesis, aphasia, unconsciousness, coma and cerebral oedema within minutes to hours after administration of iomeprol, and generally resolves within days.
The product should be used with caution in patients with conditions that disrupt the integrity of the blood brain barrier (BBB), potentially leading to increased permeability of contrast media across the BBB and increasing the risk of encephalopathy. If contrast encephalopathy is suspected, administration of iomeprol should be discontinued and appropriate medical management should be initiated.
In acute and chronic alcoholism the increase in blood brain barrier permeability facilitates the passage of the contrast medium into cerebral tissue possibly leading to CNS disorders. There is a possibility of a reduced seizure threshold in alcoholics.
In patients with a drug addiction there is also the possibility of a reduced seizure threshold.

Severe cutaneous adverse reactions
Severe cutaneous reactions (SCARs) including Steven-Johnson (SJS), toxic epidermal necrolysis (TEN), acute generalized exanthematous pustulosis (AGEP) and drug reaction with eosinophilia and systemic symptoms (DRESS), which can be life-threatening or fatal, have been reported in association with the intravascular administration of iodinated contrast agents (see Section 4.8). At the time of administration patients should be advised of the signs and symptoms and monitored closely for skin reactions. If signs and symptoms suggestive of these reactions appear, Iomeron should be stopped immediately. If the patient has developed a serious reaction such as SJS, TEN, AGEP or DRESS with the use of Iomeron, administration of Iomeron must not be restarted to this patient at any time.
Patients with phaeochromocytoma may develop severe, occasionally uncontrollable hypertensive crises during intra-arterial administration. Premedication with an alpha and beta receptor blocker is recommended in these patients.
Pronounced excitement, anxiety and pain can cause side effects or intensify reaction to the contrast medium.
A sedative may be given.
Renal impairment
In patients with moderate to severe impairment of renal function, attention should be paid to renal function parameters before re-examining the patient with a contrast media.
Preventive measures include:
- identification of high-risk patients;
- ensuring adequate hydration before CM administration, preferably by maintaining I.V. infusion before and during the procedure and until the CM has been cleared by the kidneys; - avoiding whenever possible, the administration of nephrotoxic drugs or major surgery or procedure such as renal angioplasty, until the CM has been cleared;

A combination of severe hepatic and renal impairment delays excretion of the contrast medium therefore such patients should not be examined unless absolutely necessary.
Diabetes mellitus
Care should be taken in renal impairment and diabetes. In these patients it is important to maintain hydration in order to minimise deterioration in renal function.
The presence of renal damage in diabetic patients is one of the factors predisposing to renal impairment following contrast media administration. This may precipitate lactic acidosis in patients who are taking metformin (see section 4.5 - Interaction with other medicinal products and other forms of interaction).

Paediatric population
Infants up to 1 year, especially the newborn, are particularly susceptible to electrolyte imbalance and haemodynamic alterations. Care should be taken regarding the dosage used.

Thyroid Dysfunction in Pediatric Patients 0 to 3 Years of Age

Thyroid dysfunction characterized by hypothyroidism or transient thyroid suppression has been reported after both single exposure and multiple exposures to iodinated contrast media (ICM) in pediatric patients 0 to 3 years of age.

Younger age, very low birth weight, prematurity, underlying medical conditions affecting thyroid function, admission to neonatal or pediatric intensive care units, and congenital cardiac conditions are associated with an increased risk of hypothyroidism after ICM exposure. Pediatric patients with congenital cardiac conditions may be at the greatest risk given that they often require high doses of contrast during invasive cardiac procedures.

An underactive thyroid during early life may be harmful for cognitive and neurological development and may require thyroid hormone replacement therapy. After exposure to ICM, individualize thyroid function monitoring based on underlying risk factors, especially in term and preterm neonates.

Elderly
There is special risk of reactions involving the circulatory system such that myocardial ischaemia, major arrhythmias and extrasystoles are more likely to occur. A combination of neurological disturbances and vascular pathologies present a serious complication. The probability of acute renal insufficiencies is higher in these people.

Precautions for dedicated exams
Angiography
Non-ionic contrast media have less anticoagulant activity in vitro than ionic media. Meticulous attention should therefore be paid to angiographic technique. Non ionic media should not be allowed to remain in contact with blood in a syringe, and intravascular catheters should be flushed frequently to minimise the risk of clotting which, rarely, has led to serious thromboembolic complications.
Intravascular administration should be performed, if possible, with the patient lying down. The patient should be kept in this position and closely observed for at least 30 minutes after the procedure since the majority of severe incidents occur with this time.
Venography
Special care is required when venography is performed in patients with thrombosis, phlebitis, severe ischaemic disease, local infection or a totally obstructed artero-venous system.

Effects on Driving

4.7 Effects on ability to drive and use machines

There is no known effect on the ability to drive and operate machines.
שימוש לפי פנקס קופ''ח כללית 1994 לא צוין
תאריך הכללה מקורי בסל לא צוין
הגבלות לא צוין

בעל רישום

DEXCEL LTD, ISRAEL

רישום

103 46 28522 11

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

25.07.22 - עלון לרופא 07.09.23 - עלון לרופא 06.11.23 - עלון לרופא 06.02.24 - עלון לרופא

עלון מידע לצרכן

12.07.15 - עלון לצרכן 25.07.22 - עלון לצרכן 07.09.23 - החמרה לעלון 07.11.23 - החמרה לעלון 05.02.24 - החמרה לעלון

לתרופה במאגר משרד הבריאות

איומרון 350

קישורים נוספים

RxList WebMD Drugs.com